QualityStocksNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial on Biotech Valuation Trends
Oncotelic Therapeutics (OTCQB: OTLC) was highlighted in a BioMedWire editorial examining how fair-value remeasurements under GAAP are becoming key indicators of real scientific and commercial progress in late-stage biotech pipelines. The piece notes that Oncotelic is preparing for a significant fair-value remeasurement of its 45% stake in JV entity GMP Bio following a new independent valuation suggesting a potential step-up in asset value, reinforcing the company’s position as it advances its oncology efforts. To view the full press release, visit https://ibn.fm/HKwqM About Oncotelic Therapeutics Inc. Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on the development of oncology and immunotherapy…